Board members at Father Joe’s include several executives of companies and national brands with local headquarters. The group’s corporate partners feature a similar mix of nearby businesses, such as ...

Neurocrine Biosciences has a fifty-two week low of $105.18 and a fifty-two week high of $157.98. The firm has a market capitalization of $10.87 billion, a P/E ratio of 33.13, a P/E/G ratio of 0.77 ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18 ...

For the year to December 2024, Neurocrine Biosciences had an accrual ratio of -0.15. Therefore, its statutory earnings were very significantly less than its free cashflow. To wit, it produced free ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees potential upside for Neurocrine shares with multiple ...

NASDAQ:NBIX opened at $107.22 on Wednesday. Neurocrine Biosciences, Inc. has a fifty-two week low of $105.18 and a fifty-two week high of $157.98. The stock’s 50-day moving average is $131.36 ...

RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer coverage changes suggests gradually increasing ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company specializing in neurological and endocrine-related disorders, finds itself at a critical juncture as it navigates a shifting ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine ...

SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability ...